Pàgina inicial > Resultats de la cerca: Chronic lymphocytic leukaemia
  Consells de cerca
Cerca avançada
Cerca col·leccions:
Ordena'ls per: Mostrar els resultats: Format de visualizació:
Resultats globals: 3 registres trobats en 0.02 segons.
Articles, 3 registres trobats
Articles 3 registres trobats  
1.
7 p, 442.8 KB Treatment decision-making in chronic lymphocytic leukaemia : Key factors for healthcare professionals. PRELIC study / Boque, Concepcion (Institut Català d'Oncologia) ; Abad, María Reyes (Hospital Universitario Miguel Servet (Saragossa)) ; Agustin Ferrandez, Maria Jose (Hospital Universitario Miguel Servet (Saragossa)) ; García-Goñi, Manuel (Universidad Complutense de Madrid) ; Moreno, Carolina M. (Institut d'Investigació Biomèdica Sant Pau) ; Gabás-Rivera, Clara (Outcomes 10) ; Granados, Enrique (Gilead Sciences) ; Castro-Gómez, Antonio (Gilead Sciences) ; Pardo, Carlos (Gilead Sciences) ; Lizán, Luis (Universitat Jaume I)
To explore the preferences of Spanish healthcare professionals (haematologists and hospital pharmacists) for the treatment selection of active Chronic Lymphocytic Leukaemia (CLL) patients at first relapse, condition that mainly afflicts older adults. [...]
2020 - 10.1016/j.jgo.2019.03.010
Journal of Geriatric Oncology, Vol. 11 Núm. 1 (january 2020) , p. 24-30  
Registre complet - Creative Commons
2.
7 p, 267.3 KB Long-term efficacy of first-line ibrutinib treatment for chronic lymphocytic leukaemia in patients with TP53 aberrations : a pooled analysis from four clinical trials / Allan, John N. (Weill Cornell Medicine) ; Shanafelt, Tait (Stanford University Medical Center) ; Wiestner, Adrian (National Heart, Lung, and Blood Institute) ; Moreno, Carol (Institut d'Investigació Biomèdica Sant Pau) ; O'Brien, Susan M. (University of California Irvine) ; Li, Jianling (Pharmacyclics LLC) ; Krigsfeld, Gabriel (Pharmacyclics LLC) ; Dean, James P. (Pharmacyclics LLC) ; Ahn, Inhye E. (National Heart, Lung, and Blood Institute) ; Universitat Autònoma de Barcelona
TP53 aberrations [del(17p) or TP53 mutation] predict poor survival with chemoimmunotherapy in patients with chronic lymphocytic leukaemia (CLL). We evaluated long-term efficacy and safety of first-line ibrutinib-based therapy in patients with CLL bearing TP53 aberrations in a pooled analysis across four studies: PCYC-1122e, RESONATE-2 (PCYC-1115/16), iLLUMINATE (PCYC-1130) and ECOG-ACRIN E1912. [...]
2021 - 10.1111/bjh.17984
British Journal of Haematology, Vol. 196 (december 2021) , p. 947-953  
Registre complet - Creative Commons
3.
12 p, 1.8 MB Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL : 5 years of follow-up from the phase 3 RESONATE-2 study / Burger, Jan A. (University of Texas MD Anderson Cancer Center. Department of Leukemia) ; Barr, Paul M. (Wilmot Cancer Institute, University of Rochester Medical Center) ; Robak, Tadeusz (Medical University of Lodz, Copernicus Memorial Hospital) ; Owen, Carolyn (University of Calgary. Tom Baker Cancer Centre) ; Ghia, Paolo (Università Vita-Salute San Raffaele and IRCCS Ospedale San Raffaele) ; Tedeschi, Alessandra (ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy) ; Bairey, Osnat (Tel Aviv University. Rabin Medical Center, Petah Tikva, Israel and Sackler Faculty of Medicine) ; Hillmen, Peter (University of Leeds. The Leeds Teaching Hospitals, St. James Institute of Oncology) ; Coutre, Steven E. (Stanford University School of Medicine. Stanford Cancer Center) ; Devereux, Stephen (NHS Foundation Trust. Kings College Hospital) ; Grosicki, Sebastian (Silesiam Medical University. Department of Hematology and Cancer Prevention) ; McCarthy, Helen (Royal Bournemouth General Hospital (Dorset, Regne Unit)) ; Simpson, David (North Shore Hospital) ; Offner, Fritz (Universitair Ziekenhuis Gent) ; Moreno, Carol (Institut d'Investigació Biomèdica Sant Pau) ; Dai, Sandra (Pharmacyclics LLC, an AbbVie Company) ; Lal, Indu (Pharmacyclics LLC, an AbbVie Company) ; Dean, James P. (Pharmacyclics LLC, an AbbVie Company) ; Kipps, Thomas J. (UCSD Moores Cancer Center) ; Universitat Autònoma de Barcelona
RESONATE-2 is a phase 3 study of first-line ibrutinib versus chlorambucil in chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). Patients aged ≥65 years (n = 269) were randomized 1:1 to once-daily ibrutinib 420 mg continuously or chlorambucil 0. [...]
2019 - 10.1038/s41375-019-0602-x
Leukemia, Vol. 34 (october 2019) , p. 787-798  
Registre complet - Creative Commons

Us interessa rebre alertes sobre nous resultats d'aquesta cerca?
Definiu una alerta personal via correu electrònic o subscribiu-vos al canal RSS.
Dipòsit Digital de Documents de la UAB :: Cerca :: Lliura :: Personalitza :: Ajuda
Powered by Invenio v1.1.6
Mantingut per ddd.bib@uab.cat  :: Metadades subjectes a:
Col·laborem